Dr. Anna Merlotti

Radiation Oncology S.Croce e Carle Teaching Hospital, Cuneo. Italy

[youngAIRO @airo_young]

Ieri, presso la Camera dei Deputati, durante la II edizione degli Stati Generali della Radioterapia Oncologica promossa da #AIRO, il confronto si è concentrato su formazione, innovazione e futuro!
Come #AIROGiovani, abbiamo partecipato attivamente! #RadOncs4Life

[Giulia Marvaso @GiuliaMarvaso84]

@alongi_filippo @EurUrolOncol @CiroFranzese1

[Filippo Alongi @alongi_filippo]

Here the official position of AIRO, Italian Association of Radiotherapy and Clinical Oncology in regard to IRRADIaTE, the Italian Registry of RT-Associated Urological Treatment. @EurUrolOncol . In press. https://t.co/FC1k6QmeCV thanks to @GiuliaMarvaso84 & @CiroFranzese1

[VNardone @Valerio_Nardone]

Congratulations to @PierluigiBonomo on being elected President-Elect of the Italian Society of Radiation Oncology #AIRO
His attitude, energy and dedication to #radonc will be vital to shape the future of our beloved specialty! Best wishes for the journey ahead!

[Pierluigi Bonomo @PierluigiBonomo]

Airo Giovani meeting touching on the challenges and advances of radiation therapy for pediatric and AYAs patients - kudos to all the speakers @airo_young #AIRO2025

[Pierluigi Bonomo @PierluigiBonomo]

(Un)sustainability of cancer treatment: where are we heading?
Great talk by @MassimoDiMaio75 #AIRO2025

[VNardone @Valerio_Nardone]

Congratulations to @emmadippolito for the outstanding presentation of the CRASCH trial at #AIRO2025! A remarkable contribution that highlights the strength and innovation of our research community. Well done, Emma! 👏🌟 #RadOnc #AIRO2025

[Drew Moghanaki @DrewMoghanaki]

If you’re a fan of radiation oncology and struggling to figure out why more people don’t celebrate the cancer treatments we deliver, then this editorial might be for you. @IJROBP @sueyom @NehaVapiwala

https://t.co/sa8vmX1aKx

[youngAIRO @airo_young]

🚀 Un’altra grande #opportunità per i nostri soci!
#AIRO bandisce 5 borse di studio per la partecipazione a corsi residenziali #ESTRO @ESTRO_RT
📌 Scadenza per la presentazione delle domande: 16 ottobre 2025.
📎 Il bando completo è disponibile in allegato.

[Andrea R. Filippi @AndrearicFili]

Key findings include:
1. Excellent safety and tolerability in an elderly, unfit population.
2. Median overall survival nearly doubled compared to existing radiotherapy.
3. Promising results from combining radiotherapy with palliative doses and immunotherapy.

[Pierluigi Bonomo @PierluigiBonomo]

How do patients with HPV-positive oropharyngeal cancer experience their disease and relate to their treatment decision-making? Happy to share an insight on this still overlooked topic @ctRO_journal
https://t.co/PBN931ISLU

[Gustavo @gusviani]

🚀 Could Radiation “Heat Up” Cold Tumors? New Evidence in NSCLC! @OncoAlert

🎯 Objective
Evaluate whether ☢️ enhances immunotherapy efficacy in TMB-low, PDL1-null, or Wnt-mutated NSCLC

🏥 Methods
• Design: Phase 2 RCT (NCT02492568)
• Arms: Pembrolizumab ± SBRT (3x8Gy before ICI)
• Samples: 293 blood/tumor biospecimens
• Analyses: Multiomics, TCR-seq, GSEA, RECIST

📊 Key Findings
• ☢️ upregulated IFNγ, antigen processing & T/B cell activation at distant sites
• Clonal TCR expansion seen in tumors + blood
• PFS benefit in “cold” tumors with SBRT-ICI combo
• Suggests abscopal priming & cold-to-hot TME conversion

🧠 Clinical implication: RT may unlock ICI resistance in cold NSCLC

[Dr. Anna Merlotti @AnnaMerlotti]

@ASCOPost @jingxuan_zhao @CostAnEffect These data should inform opinions on the importance of supporting universal health services, their sustainability (collaboration with pharmaceutical companies is necessary!), and equal access to care.

[The ASCO Post @ASCOPost]

Study by @jingxuan_zhao, @CostAnEffect, et al, shows 2-year survival gaps widened between uninsured and privately insured patients with stage IV #Melanoma, #NSCLC, and #RCC after ICI introduction.

🔗https://t.co/nkCcq3NXhm

[ESTRO @ESTRO_RT]

👏 Proud to see ESTRO President-Elect Prof Barbara Jereczek-Fossa represent #radiotherapy at @CancerPatientsE “Access for All” event in Brussels 🇪🇺
She spotlighted radiotherapy’s role in equitable cancer care across Europe. At ESTRO, we’re committed to that vision! ✨

[Jason Beckta @drbeckta]

"Radiation Oncologists - evidently not content with spending the first two decades of the 21st century running trial after trial attempting to reduce or omit their own modality from modern cancer therapy - have now shifted their efforts to an entirely new level..."

[Tumori Journal @TumoriJ]

🆕This paper aims to provide a comprehensive approach to target volume definition in cutaneous and non-cutaneous squamous cell carcinoma patients👇

Perineural invasion and parotid involvement in auricular cutaneous SCC➡️Which volumes to treat in postoperative #radiotherapy❓

https://t.co/OUJzfluqeo

[Radiotherapy & Oncology @RO_GreenJournal]

🧠 New review sheds light on how to select and delineate post-op radiotherapy target volumes in oral cavity SCC. A must-read for H&N specialists
🔗https://t.co/XrLxhjkQJM
#RadOnc #HeadandNeckCancer #OralCancer #Radiotherapy

[youngAIRO @airo_young]

🗓️ Febbraio è il mese dedicato alle 𝗠𝗮𝗹𝗮𝘁𝘁𝗶𝗲 𝗥𝗮𝗿e. Tra queste, i 𝗧𝘂𝗺𝗼𝗿𝗶 𝗥𝗮𝗿𝗶 rappresentano una sfida significativa: progetto 𝗥𝗔𝗥𝗘𝗖𝗔𝗥𝗘𝗻𝗲𝘁 (https://t.co/H0HHSJKM1m)
#RareButNotAlone #TumoriRari #RadioterapiaOncologica

[Icro Meattini @Icro_Meattini]

The Italian health data system is broken - The Lancet Regional Health – Europe

https://t.co/ozEoknCgZM